Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors

Jennifer Choi, Ronald Anderson, Ada Blidner, Tim Cooksley, Michael Dougan, Ilya Glezerman, Pamela Ginex, Monica Girotra, Dipti Gupta, Douglas Johnson, Vickie R. Shannon, Maria Suarez-Almazor, Bernardo L. Rapoport*, Mario E. Lacouture

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Immune checkpoint inhibitors (ICIs) frequently result in cutaneous immune-related adverse events (IrAEs). Although the majority of these events are mild-to-moderate in severity, up to 5% are severe, which may lead to morbidity and dose interruption or discontinuation of ICI therapy. In addition, up to 25% of dermatologic IrAEs are corticosteroid-refractory or corticosteroid-dependent. These 2020 MASCC recommendations cover the diagnosis and management of cutaneous IrAEs with a focus on moderate-to-severe and corticosteroid-resistant events. Although the usage of immune-suppressive therapy has been advocated in this setting, there is a lack of randomized clinical trial data to provide a compelling level of evidence of its therapeutic benefit.

Original languageEnglish (US)
Pages (from-to)6119-6128
Number of pages10
JournalSupportive Care in Cancer
Volume28
Issue number12
DOIs
StatePublished - Dec 2020

Keywords

  • Bullous dermatoses
  • Corticosteroids
  • Cutaneous IrAEs
  • Inflammatory dermatitis
  • Pruritus
  • Skin rash
  • Vitiligo

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors'. Together they form a unique fingerprint.

Cite this